| Literature DB >> 31750326 |
Qi-Yue Chen1, Zhi-Liang Hong1, Qing Zhong1, Zhi-Yu Liu1, Xiao-Bo Huang1, Si-Jin Que1, Ping Li1, Jian-Wei Xie1, Jia-Bin Wang1, Jian-Xian Lin1, Jun Lu1, Long-Long Cao1, Mi Lin1, Ru-Hong Tu1, Chao-Hui Zheng1, Chang-Ming Huang1.
Abstract
BACKGROUND: The incidence of proximal gastric cancer (GC) is increasing, and methods for the prediction of the long-term survival of proximal GC patients have not been well established. AIM: To develop nomograms for the prediction of long-term survival among proximal GC patients.Entities:
Keywords: Nomogram; Prediction; Preoperative; Prognosis; Proximal gastric cancer
Year: 2019 PMID: 31750326 PMCID: PMC6854413 DOI: 10.12998/wjcc.v7.i21.3419
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Flow chart depicting the patient selection process.
Figure 2X-tile used to confirm the cutoff values for CEA (A) and CA19-9 (B).
Comparison of preoperative and postoperative clinicopathology data in the training and validation sets
| Model set ( | Validation set ( | |||
| Age (yr) | 0.648 | |||
| < 65 | 313 | 98 | ||
| ≥ 65 | 247 | 88 | ||
| Gender | 0.446 | |||
| Female | 98 | 35 | ||
| Male | 462 | 151 | ||
| BMI (kg/m2) | 0.382 | |||
| < 25 | 473 | 162 | ||
| ≥ 25 | 87 | 24 | ||
| Preoperative tumor size(cm) | 0.736 | |||
| < 5 | 272 | 93 | ||
| ≥ 5 | 288 | 93 | ||
| Preoperative N stage | 0.965 | |||
| N0 | 269 | 89 | ||
| N+ | 291 | 97 | ||
| Preoperative T stage | 0.066 | |||
| T1-3 | 190 | 77 | ||
| T4 | 370 | 109 | ||
| Preoperative CA19-9 (U/mL) | 0.643 | |||
| < 33.35 | 463 | 151 | ||
| ≥ 33.35 | 97 | 35 | ||
| Preoperative CEA (µg/mL) | 0.487 | |||
| < 4 | 365 | 116 | ||
| ≥ 4 | 195 | 70 | ||
| ASA score | 0.511 | |||
| 1 | 309 | 114 | ||
| 2 | 195 | 58 | ||
| 3 | 55 | 14 | ||
| 4 | 1 | 0 | ||
| Accompanying disease | 0.087 | |||
| No | 359 | 132 | ||
| Yes | 201 | 54 | ||
| History of epigastric operation | 0.432 | |||
| No | 544 | 183 | ||
| Yes | 16 | 3 | ||
| Preoperative Charlson score | 0.311 | |||
| 0 | 368 | 133 | ||
| 1-2 | 184 | 50 | ||
| ≥ 3 | 8 | 3 | ||
| HB, g/L | 0.208 | |||
| ≥ 9.0 | 500 | 172 | ||
| < 9.0 | 60 | 14 | ||
| ALB, g/L | 0.096 | |||
| ≥ 35 | 418 | 150 | ||
| < 35 | 142 | 36 | ||
| Fibrinogen, g/L | 0.067 | |||
| < 4 | 364 | 107 | ||
| ≥ 4 | 196 | 79 | ||
| 3- to 6-mo weight reduction | 0.835 | |||
| No | 321 | 105 | ||
| Yes | 239 | 81 | ||
| Lymph node ratio | 0.158 ± 0.200 | 0.192 ± 0.227 | 0.069 | |
| Postoperative T stage | 0.248 | |||
| T1 | 73 | 35 | ||
| T2 | 67 | 19 | ||
| T3 | 162 | 54 | ||
| T4a | 258 | 78 | ||
| Postoperative N stage | 0.583 | |||
| N0 | 169 | 65 | ||
| N1 | 95 | 26 | ||
| N2 | 101 | 34 | ||
| N3 | 195 | 61 | ||
| Involvement of the esophagus with the tumor | 0.028 | |||
| No | 370 | 139 | ||
| Yes | 190 | 47 | ||
| Postoperative tumor size (cm) | 0.233 | |||
| < 5 | 231 | 86 | ||
| ≥ 5 | 329 | 100 | ||
| LVI | 0.72 | |||
| No | 408 | 133 | ||
| Yes | 152 | 53 | ||
| Postoperative blood transfusion | 0.745 | |||
| No | 498 | 167 | ||
| Yes | 62 | 19 | ||
| General complications | 0.495 | |||
| No | 486 | 165 | ||
| Yes | 74 | 21 | ||
| Presence of digestive tract fistula | 0.498 | |||
| No | 552 | 182 | ||
| Yes | 8 | 4 | ||
| Postoperative obstruction | 1 | |||
| No | 553 | 184 | ||
| Yes | 7 | 2 | ||
| Infection of incisional wound | 0.339 | |||
| No | 555 | 186 | ||
| Yes | 5 | 0 | ||
| Intra-abdominal infection | 0.422 | |||
| No | 549 | 184 | ||
| Yes | 11 | 2 | ||
| Pulmonary infection | 0.459 | |||
| No | 521 | 170 | ||
| Yes | 39 | 16 | ||
| Peritoneal lymphatic fistula | 0.751 | |||
| No | 550 | 182 | ||
| Yes | 10 | 4 | ||
| Intra-abdominal hemorrhage | 0.74 | |||
| No | 552 | 183 | ||
| Yes | 8 | 3 | ||
| Neoadjuvant chemotherapy | 1 | |||
| No | 548 | 183 | ||
| Yes | 12 | 3 | ||
| Adjuvant chemotherapy | 0.069 | |||
| No | 258 | 100 | ||
| Yes | 302 | 86 | ||
Preoperative analysis of overall survival
| Preoperative tumor size(cm) | < 0.001 | 0.012 | ||
| < 5 | Ref | Ref | ||
| ≥ 5 | 2.953 (2.227-3.915) | 1.480 (1.090-2.010) | ||
| Preoperative N stage | < 0.001 | < 0.001 | ||
| N0 | Ref | Ref | ||
| N+ | 3.219 (2.428-4.268) | 2.069 (1.536-2.787) | ||
| Preoperative T stage | < 0.001 | < 0.001 | ||
| T1-3 | Ref | Ref | ||
| T4 | 4.550 (3.132-6.609) | 2.767 (1.846-4.148) | ||
| Preoperative CA19-9 (U/mL) | < 0.001 | 0.003 | ||
| < 33.35 | Ref | Ref | ||
| ≥ 33.35 | 2.250 (1.750-2.894) | 1.569 (1.166-2.110) | ||
| ASA score | < 0.001 | < 0.001 | ||
| 1 | Ref | Ref | ||
| 2 | 1.725 (1.299-2.289) | 1.675 (1.257-2.230) | ||
| 3 | 3.805 (2.677-5.409) | 3.257 (2.271-4.670) | ||
| 3- to 6-mo weight loss | < 0.001 | 0.036 | ||
| No | Ref | Ref | ||
| Yes | 1.588 (1.231-2.049) | 1.316 (1.019-1.701) | ||
| Age (yr) | 0.008 | |||
| < 65 | Ref | |||
| ≥ 65 | 1.412 (1.095-1.821) | |||
| Gender | 0.318 | |||
| Female | Ref | |||
| Male | 1.178 (0.854-1.625) | |||
| BMI (kg/m2) | 0.473 | |||
| <25 | Ref | |||
| ≥ 25 | 0.875 (0.609-1.259) | |||
| Accompanying disease | 0.673 | |||
| No | Ref | |||
| Yes | 0.944 (0.724-1.232) | |||
| History of abdominal surgery | 0.704 | |||
| No | Ref | |||
| Yes | 1.146 (0.566-2.321) | |||
| Preoperative Charlson score | ||||
| 0 | Ref | |||
| 1-2 | 1.007 (0.768-1.322) | 0.959 | ||
| ≥ 3 | 2.202 (0.973-4.982) | 0.058 | ||
| Preoperative CEA (µg/mL) | <0.001 | |||
| < 4 | Ref | |||
| ≥ 4 | 1.673 (1.294-2.164) | |||
| HB, g/L | 0.265 | |||
| ≥ 9.0 | Ref | |||
| < 9.0 | 1.239 (0.850-1.808) | |||
| ALB, g/L | 0.014 | |||
| ≥ 35 | Ref | |||
| < 35 | 1.410 (1.072-1.854) | |||
| Fibrinogen, g/L | 0.003 | |||
| < 4 | Ref | |||
| ≥ 4 | 1.471 (1.137-1.904) | |||
Postoperative analysis of overall survival
| Postoperative T stage | < 0.001 | 0.005 | ||
| T1 | Ref | Ref | ||
| T2 | 2.743 (1.054-7.139) | 2.210 (0.843-5.794) | ||
| T3 | 6.359 (2.759-14.657) | 2.730 (1.130-6.594) | ||
| T4a | 9.829 (4.345-22.235) | 3.847 (1.595-9.278) | ||
| Postoperative N stage | < 0.001 | < 0.001 | ||
| N0 | Ref | Ref | ||
| N1 | 1.371 (0.820-2.290) | 0.962 (0.564-1.639) | ||
| N2 | 1.984 (1.250-3.151) | 1.251 (0.767-2.041) | ||
| N3 | 5.967 (4.109-8.663) | 2.659 (1.708-4.139) | ||
| Postoperative tumor size(cm) | < 0.001 | 0.022 | ||
| < 5 | Ref | Ref | ||
| ≥ 5 | 2.938 (2.172-2.973) | 1.503 (1.060-2.132) | ||
| Lymphatic vascular infiltration (LVI) | < 0.001 | < 0.001 | ||
| No | Ref | Ref | ||
| Yes | 3.185 (2.447-4.146) | 2.690 (2.036-3.554) | ||
| Postoperative blood transfusion | < 0.001 | 0.025 | ||
| No | Ref | Ref | ||
| Yes | 1.971 (1.402-2.771) | 1.505 (1.052-2.153) | ||
| General complications | 0.001 | 0.028 | ||
| No | Ref | Ref | ||
| Yes | 1.784 (1.278-2.490) | 1.477 (1.042-2.093) | ||
| Digestive tract fistula | 0.125 | |||
| No | Ref | |||
| Yes | 2.001 (0.825-4.855) | |||
| Postoperative obstruction | 0.033 | |||
| No | Ref | |||
| Yes | 2.629 (1.083-6.386) | |||
| Incisional infection | 0.984 | |||
| No | Ref | |||
| Yes | 0.986 (0.245-3.966) | |||
| Abdominal infection | 0.964 | |||
| No | Ref | |||
| Yes | 1.021 (0.421-2.476) | |||
| Pulmonary infection | 0.001 | |||
| No | Ref | |||
| Yes | 2.104 (1.378-3.211) | |||
| Peritoneal lymphatic fistula | 0.565 | |||
| No | Ref | |||
| Yes | 1.297 (0.535-3.147) | |||
| intra-Abdominal hemorrhage | 0.093 | |||
| No | Ref | |||
| Yes | 2.136 (0.880-5.181) | |||
| Tumor involvement of the esophagus | 0.328 | |||
| No | Ref | |||
| Yes | 1.141 (0.876-1.487) | |||
| Neoadjuvant chemotherapy | 0.012 | |||
| No | Ref | |||
| Yes | 2.480 (1.225-5.022) | |||
| Adjuvant chemotherapy | ||||
| No | Ref | |||
| Yes | 1.166 (0.902-1.507) | 0.242 | ||
| Lymph node ratio | 1.697 (0.998-2.867) | 0.053 | ||
Figure 3Preoperative nomogram for predicting overall survival in proximal gastric cancer patients after operation (C-index = 0.751).
Figure 4Postoperative 3-year and 5-year overall survival rate calibration curves. A: Training set calibration curve for the preoperative nomogram for predicting the 3-year OS; B: Validation set calibration curve for the preoperative nomogram for predicting the 3-year OS; C: Training set calibration curve for the preoperative nomogram for predicting the 5-year OS; D: Validation set calibration curve for the preoperative nomogram for predicting the 5-year OS. OS: Overall survival.
Figure 5Survival curve cutoff points for the preoperative nomogram quartiles.
Figure 6Nomogram for predicting overall survival in postoperative proximal gastric cancer patients (C-index = 0.754).
Figure 7Postoperative nomogram 3-year and 5-year overall survival rate calibration curves. A: Calibration curve for the postoperative nomogram for predicting the three-year OS using the training set; B: Calibration curve for the postoperative nomogram for predicting the three-year OS using the validation set; C: Calibration curve for the postoperative nomogram for predicting the five-year OS using the training set; D: Calibration curve for the postoperative nomogram for predicting the five-year OS using the validation set. OS: Overall survival.
Figure 8Survival curve cutoff points for the postoperative nomogram quartiles.
Preoperative and postoperative nomograms accurately predicting overall survival in upper stomach cancer patients
| Area under the curve | 0.811 | 0.799 | 0.821 | 0.774 |
| Cutoff point | 18 | 18 | 18 | 18 |
| Sensitivity, % | 0.736 | 0.706 | 0.768 | 0.855 |
| Specificity, % | 0.753 | 0.764 | 0.744 | 0.598 |
| Positive predictive value, % | 0.749 | 0.818 | 0.755 | 0.704 |
| Negative predictive value, % | 0.741 | 0.634 | 0.828 | 0.787 |
| Positive likelihood ratio | 2.98 | 2.99 | 3 | 2.127 |
| Negative likelihood ratio | 0.351 | 0.385 | 0.304 | 0.242 |